AstraZeneca to acquire TeneoTwo and T cell engager
5 July 2022 07:00 BST AstraZeneca to acquire TeneoTwo and its clinical-stage T-cell engager, strengthening haematological cancer pipeline TNB-486 will be evaluated in multiple types of lymphoma AstraZeneca today announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)[i], including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluation in relapsed and refractory B-cell non-Hodgkin lymphoma[1]. The acquisition of TNB-486 aims to accelerate the development of this potential new medicine for B-cell haematologic malignancies, including diffuse